Karim, 2019 - Google Patents
Estrogen Receptor Beta Ligands Exert Pro-Myelinating Effects by Altering Pro-Inflammatory Responses in an Animal Model of Multiple SclerosisKarim, 2019
View PDF- Document ID
- 5872921743575335882
- Author
- Karim H
- Publication year
External Links
Snippet
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease with no known etiology nor cure. Current immunomodulatory drugs reduce inflammation or prevent leukocyte egress from lymph nodes, but neither halt disease …
- 230000027455 binding 0 title abstract description 227
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2690670C2 (en) | Reduced levels or activity of systemic regulatory t cells for treating disease or cns injury | |
Aharoni | Immunomodulation neuroprotection and remyelination–The fundamental therapeutic effects of glatiramer acetate: A critical review | |
Gilgun-Sherki et al. | Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis | |
AU2014340210A1 (en) | Use of semaphorin-4D binding molecules for treating neurodegenerative disorders | |
Meyer Zu Horste et al. | Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies | |
US20170184612A1 (en) | Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder | |
Laouarem et al. | Functional cooperation of the hedgehog and androgen signaling pathways during developmental and repairing myelination | |
JP2006512396A (en) | Methods for inducing and maintaining immune tolerance | |
Perera et al. | Active immunization with myelin-derived altered peptide ligand reduces mechanical pain hypersensitivity following peripheral nerve injury | |
WO2019152516A1 (en) | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | |
CN112512554A (en) | Immunodominant proteins and fragments in multiple sclerosis | |
CN106030302B (en) | treatment of neurodegenerative diseases | |
Dong et al. | Pro-inflammatory cytokines and leukocyte integrins associated with chronic neuropathic pain in traumatic and inflammatory neuropathies: Initial observations and hypotheses | |
Dwyer et al. | B cell treatment promotes a neuroprotective microenvironment after traumatic brain injury through reciprocal immunomodulation with infiltrating peripheral myeloid cells | |
Karim | Estrogen Receptor Beta Ligands Exert Pro-Myelinating Effects by Altering Pro-Inflammatory Responses in an Animal Model of Multiple Sclerosis | |
JP2020522499A (en) | Treatment of neuroinflammatory diseases | |
JP2020530846A (en) | Method | |
CN115697391A (en) | Improved vaccine formulations | |
van Noort et al. | The pathogenesis of multiple sclerosis: a series of unfortunate events | |
Harry | Microglia: neuroprotective and neurodestructive properties | |
Shang et al. | B-cell targeted therapies in autoimmune encephalitis: mechanisms, clinical applications, and therapeutic potential | |
Khaw | Assessment of the impact of early life trauma, changes in estrogen signaling, and neurotoxic molecules in a mouse model of multiple sclerosis | |
Eissa et al. | Interrelation Between the Immune and the Nervous Systems in the Context of Cerebellar Development and Developmental Disorders | |
Lozinski | Interactions of neurofibrosis and oligodendrogenesis following demyelination: Modulation by aging and exercise | |
Pouzol | Preclinical development of ACT-1004-1239, a potent and selective CXCR7/ACKR3 antagonist in multiple sclerosis treatment |